Long-term results of intravesical bacillus calmette-guérin therapy for stage T1 superficial bladder cancer

Urology

Volumn 55, Issue 5, 2000, Pages 673-678

  Brake, Michael ^a   Loertzer, Hagen ^a   Horsch, Reinhold ^a   Keller, Hansjörg ^a  

^a Klinikum Offenburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER STAGING; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTRAVESICAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TIME; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0034184840     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00591-9     Document Type: Article

References (30)

1. Kaubisch S, Lum BL, Reese J, et al: Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 146: 28-31, 1991.
2. Lamm DL, Riggs DR, Traynelis CL, et al: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: 1444-1450, 1995.
3. Boccon Gibod L, Leleu C, Herve JM, et al: Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression. Eur Urol 16: 401-404, 1989.
4. Samodai L, Kiss L, Kolozsy Z, et al: The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer. Int Urol Nephrol 23: 559-567, 1991.
5. Cookson MS, and Sarosdy MF: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol 148: 797-801, 1992.
6. Jakse G, Loidl W, Seeber G, et al: Stage 1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 137: 39-43, 1987.
7. Stöckle M, Alken P, Engelmann U, et al: Radical cystectomy - often too late? Eur Urol 13: 361-367, 1987.
8. Eure GR, Cundiff MR, and Schellhammer PF: Bacillus Calmette-Guérin therapy for high risk stage T1 superficial bladder cancer. J Urol 147: 376-379, 1992.
9. Gohji K, Nomi M, Okamoto M, et al: Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 53: 308-313, 1999.
10. Herr HW, Wartinger DD, Fair WR, et al: Bacillus Calmette-Guérin therapy for superficial bladder cancer: a 10-year follow-up. J Urol 147: 1020-1023, 1992.
11. Pansadoro V, Emiliozi P, Defidio L, et al: Bacillus Calmette-Guérin in the treatment of stage 1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 154: 2054-2058, 1995.
12. Serretta V, Piazza S, Pavone C, et al: Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1,G3 transitional cell carcinoma of the bladder. Urology 47: 647-651, 1996.
13. Herr HW, Laudone VP, Badalament RA, et al: BCG therapy alters the progression of superficial bladder cancer. J Clin Oncol 6: 1450-1455, 1988.
14. Khanna OP, Son DL, Mazer H, et al: Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guérin or adriamycin. Urology 35: 101-108, 1990.
15. Hermann GG, Horn T, and Steven K: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 159: 91-94, 1998.
16. Böhle A, and Jocham D: Die Intravesikale Immuntherapie mit Bacillus Calmette-Guérin. Fakten, Vergleiche, Ergebnisse. Stuttgart, G. Fischer, 1998, vol 6, p 77.
17. Malkowicz SB, Nichols P, Lieskovsky G, et al: The role of radical cystectomy in the management of high grade superficial bladder cancer (Pa, P1, Pis and P2). J Urol 144: 641-645, 1990.
18. Birch BRP, and Harland SJ: The pT1G3 bladder tumor. Br J Urol 64: 109-116, 1989.
19. Rübben H, Lutzeyer W, Ebbinghaus KD, et al: Adjuvant radiotherapy in Ta, T1 and T2 bladder tumors after transurethral resection: a retrospective study, in Wallace DMA (Ed): Bladder Cancer, Part B: Radiation, Local and Systemic Chemotherapy and New Treatment Modalities. New York, Allan R Liss, 1984, pp 21-22.
20. Slack NH, Bross ID, and Prout GR: Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 9: 393-396, 1977.
21. Kurth KH, Sylvester R, de Pauw M, et al: Intracavitary treatment of transitional cell carcinoma of the bladder. Questions and lessons after 27 years of experience. Prog Clin Biol Res 310: 125-132, 1989.
22. Lamm DL, and Griffith JG: Intravesical therapy: does it alter the natural history of superficial bladder cancer? Semin Urol 10: 39-44, 1992.
23. Dalton JT, Wientjes GM, Badalament RA, et al: Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51: 5144-5152, 1992.
24. Bohle A, Thanhäuser A, Ulmer AJ, et al: Dissecting the immunobiological effects of bacillus Calmette Guérin (BCG) in vitro. Evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150: 1932-1937, 1993.
25. Herr H, and Jakse G: pT1 bladder cancer. Eur Urol 20: 1-8, 1990.
26. Ooms ECM, Anderson WAD, Alons CL, et al: An analysis of the performance of pathologists in the grading of bladder tumours. Hum Pathol 14: 140-143, 1983.
27. Rübben H, and Jocham D: Therapie des oberflächlichen Blasenkarzinoms. Urologe A 30: 2-9, 1991.
28. Heney NM, Nocks BN, Daly JJ, et al: pTa and pT1 bladder cancer: location, recurrence and progression. Br J Urol 54: 152-157, 1982.
29. Klän R, Loy V, and Huland H: Residual tumor discovered in routine second transurethral resection in patients with stage pT1 transitional cell carcinoma of the bladder. J Urol 146: 316-318, 1991.
30. Zbar B, Bernstein ID, and Rapp HJ: Suppression of tumor growth at the site of infection with living BCG. J Natl Cancer Inst 46: 831-839, 1971.